George E. Kaugars DDS (Professor) , Sol Silverman Jr. MA, DDS (Professor) , John G.L. Lovas DDS (Associate Professor) , Richard B. Brandt PhD (Professor) , William T. Riley PhD (Associate Professor) , Quyen Dao BS (Graduate Student) , Vishwa N. Singh PhD (Assistant Director) , John Gallo BS, MT (Certified Medical Technologist)
{"title":"抗氧化补充剂治疗口腔白斑的临床试验","authors":"George E. Kaugars DDS (Professor) , Sol Silverman Jr. MA, DDS (Professor) , John G.L. Lovas DDS (Associate Professor) , Richard B. Brandt PhD (Professor) , William T. Riley PhD (Associate Professor) , Quyen Dao BS (Graduate Student) , Vishwa N. Singh PhD (Assistant Director) , John Gallo BS, MT (Certified Medical Technologist)","doi":"10.1016/0030-4220(94)90039-6","DOIUrl":null,"url":null,"abstract":"<div><p>Seventy-nine patients with oral leukoplakia that was histologically verified as either hyperkeratosis or epithelial dysplasia with hyperkeratosis were enrolled in an antioxidant supplementation program for the treatment of the oral lesions. The patients received 30 mg of beta-carotene, 1000 mg of ascorbic acid, and 800 IU of alpha-tocopherol per day for 9 months. Clinical improvement of the oral lesion was noted in 55.7% of the patients and was more likely to occur in patients who reduced their use of alcohol or tobacco (<em>p</em> = 0.0056). Although risk-factor reduction was important, approximately half of the patients who did not alter their exposure to either alcohol or tobacco showed clinical improvement. The antioxidant supplementation significantly increased serum and tissue levels of beta-carotene, ascorbic acid, and alpha-tocopherol, but these changes did not correlate strongly with clinical improvement.</p></div>","PeriodicalId":100992,"journal":{"name":"Oral Surgery, Oral Medicine, Oral Pathology","volume":"78 4","pages":"Pages 462-468"},"PeriodicalIF":0.0000,"publicationDate":"1994-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0030-4220(94)90039-6","citationCount":"85","resultStr":"{\"title\":\"A clinical trial of antioxidant supplements in the treatment of oral leukoplakia\",\"authors\":\"George E. Kaugars DDS (Professor) , Sol Silverman Jr. MA, DDS (Professor) , John G.L. Lovas DDS (Associate Professor) , Richard B. Brandt PhD (Professor) , William T. Riley PhD (Associate Professor) , Quyen Dao BS (Graduate Student) , Vishwa N. Singh PhD (Assistant Director) , John Gallo BS, MT (Certified Medical Technologist)\",\"doi\":\"10.1016/0030-4220(94)90039-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Seventy-nine patients with oral leukoplakia that was histologically verified as either hyperkeratosis or epithelial dysplasia with hyperkeratosis were enrolled in an antioxidant supplementation program for the treatment of the oral lesions. The patients received 30 mg of beta-carotene, 1000 mg of ascorbic acid, and 800 IU of alpha-tocopherol per day for 9 months. Clinical improvement of the oral lesion was noted in 55.7% of the patients and was more likely to occur in patients who reduced their use of alcohol or tobacco (<em>p</em> = 0.0056). Although risk-factor reduction was important, approximately half of the patients who did not alter their exposure to either alcohol or tobacco showed clinical improvement. The antioxidant supplementation significantly increased serum and tissue levels of beta-carotene, ascorbic acid, and alpha-tocopherol, but these changes did not correlate strongly with clinical improvement.</p></div>\",\"PeriodicalId\":100992,\"journal\":{\"name\":\"Oral Surgery, Oral Medicine, Oral Pathology\",\"volume\":\"78 4\",\"pages\":\"Pages 462-468\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1994-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0030-4220(94)90039-6\",\"citationCount\":\"85\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Surgery, Oral Medicine, Oral Pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/0030422094900396\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Surgery, Oral Medicine, Oral Pathology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0030422094900396","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A clinical trial of antioxidant supplements in the treatment of oral leukoplakia
Seventy-nine patients with oral leukoplakia that was histologically verified as either hyperkeratosis or epithelial dysplasia with hyperkeratosis were enrolled in an antioxidant supplementation program for the treatment of the oral lesions. The patients received 30 mg of beta-carotene, 1000 mg of ascorbic acid, and 800 IU of alpha-tocopherol per day for 9 months. Clinical improvement of the oral lesion was noted in 55.7% of the patients and was more likely to occur in patients who reduced their use of alcohol or tobacco (p = 0.0056). Although risk-factor reduction was important, approximately half of the patients who did not alter their exposure to either alcohol or tobacco showed clinical improvement. The antioxidant supplementation significantly increased serum and tissue levels of beta-carotene, ascorbic acid, and alpha-tocopherol, but these changes did not correlate strongly with clinical improvement.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
